AKT1 and neoplasm: As shown in Figure 6G, CDDP treatment up-regulated the phosphorylation of AKT and cyclin A, while consistent with the in vitro results, RY-2f treatment decreased the phosphorylation of AKT and cyclin A in tumor tissues.